Pharming Group N.V. to Report First Quarter 2024 Financial Results
Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) has announced that it will be releasing its preliminary (unaudited) first quarter 2024 financial results for the period ended March 31 on Wednesday, May 8, 2024.
To provide further insights into the financial performance, Pharming will be hosting a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on May 8, 2024. Those interested in participating in the conference call are required to register in advance using the provided link. Registered participants will receive dial-in information and a unique PIN to access the call.
The company has emphasized that only questions from dial-in attendees will be entertained during the conference call. Additionally, a live webcast of the presentation will be available for those who register in advance using the provided link.
Pharming Group N.V. is a global biopharmaceutical company that focuses on developing therapies for rare, debilitating, and life-threatening diseases. The company’s innovative portfolio includes protein replacement therapies, precision medicines, small molecules, biologics, and gene therapies in various stages of development.
Headquartered in Leiden, the Netherlands, Pharming serves patients in over 30 markets across North America, Europe, the Middle East, Africa, and Asia-Pacific. For more information about Pharming Group N.V., visit www.pharming.com and connect with the company on LinkedIn.
For further information, interested individuals can contact Pharming Group in Leiden, The Netherlands, or reach out to FTI Consulting in London, UK, and LifeSpring Life Sciences Communication in Amsterdam, The Netherlands.